SCHEMBL30633282

SCHEMBL30633282

Nc1n[nH]c2ccc(-c3ccnc(NC(=O)Nc4cccc(OCc5cccc(F)c5)c4)c3)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.49
▸ F10 P00742 3/20 0.46
▸ F2 P00734 1/20 0.46
▸ ELANE P08246 1/20 0.46
▸ KDR P35968 6/20 0.46
▸ LCK P06239 2/20 0.46
▸ FYN P06241 2/20 0.46
▸ CSF1R P07333 2/20 0.46
▸ LYN P07948 2/20 0.46
▸ KIT P10721 2/20 0.46
▸ FLT1 P17948 2/20 0.46
▸ FLT4 P35916 2/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ BLK P51451 2/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ SRC P12931 1/20 0.46
▸ PIK3C3 Q8NEB9 1/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26685995 1.00 MAPK1 (0.49) MAPK1F10F2ELANEKDR
SCHEMBL30633375 0.94 F10 (0.49) MAPK1F10F2ELANEKDR
SCHEMBL26685900 0.94 F10 (0.49) MAPK1F10F2ELANEKDR
SCHEMBL30633297 0.92 MEN1 (0.48) MAPK1F10KDRKITFLT3
SCHEMBL26686298 0.92 MEN1 (0.48) MAPK1F10KDRKITFLT3
SCHEMBL30633305 0.88 KDR (0.57) MAPK1KDRLCKFYNCSF1R
SCHEMBL26686045 0.88 KDR (0.57) MAPK1KDRLCKFYNCSF1R
SCHEMBL30633302 0.87 F10 (0.46) MAPK1F10F2KDRLCK
SCHEMBL26686210 0.87 F10 (0.46) MAPK1F10F2KDRLCK
SCHEMBL30633357 0.83 FLT1 (0.47) MAPK1KDRLCKFYNCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB MAPK1 163/4885F10 2348/4885F2 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback